Literature DB >> 16116645

High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.

Peter T Lin1, Beth A Martin, Ann B Weinacker, Yuen T So.   

Abstract

We describe a 48-year-old woman with seronegative myasthenia gravis (MG) and high-titer of anti-MuSK antibody. She had severe bulbar and respiratory weakness with minimal limb weakness for 2 years. Her disease responded poorly to all the conventional immunosuppressive regimens. Treatment with immunoablative dose of cyclophosphamide led to dramatic and sustained remission of her symptoms. High-dose cyclophosphamide is an effective alternative in patients with unusually refractory disease. Muscle Nerve, 2005.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16116645     DOI： 10.1002/mus.20411

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  8 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

3.  Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.

Authors:  Enrique Gomez-Figueroa; Sofía Garcia-Trejo; Lisette Bazan-Rodriguez; Roberto Cervantes-Uribe; German Chac-Lezama; Juan Carlos López-Hernández; Steven Vargas-Cañas
Journal:  J Neurol       Date:  2019-11-12       Impact factor: 4.849

Review 4.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

5.  Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.

Authors:  Agnes van Sonderen; Paul W Wirtz; Jan J G M Verschuuren; Maarten J Titulaer
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 6.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

7.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

Review 8.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.